The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection

2002 • 6,505 citations

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

2001 • 6,133 citations

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

2009 • 3,503 citations

Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C

2004 • 2,888 citations

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

2011 • 2,514 citations

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

2011 • 2,404 citations

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

2009 • 1,176 citations

Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

2009 • 1,095 citations

Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

2009 • 1,025 citations

Telaprevir for Previously Treated Chronic HCV Infection

2010 • 711 citations

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

2010 • 698 citations

Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection

2009 • 516 citations

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

2010 • 330 citations

SCH 503034, a Novel Hepatitis C Virus Protease Inhibitor, Plus Pegylated Interferon α-2b for Genotype 1 Nonresponders

2007 • 317 citations

Hepatitis C virus resistance to protease inhibitors

2011 • 297 citations

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C

2007 • 258 citations

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection

2010 • 116 citations

Mechanistic Characterization of GS-9190 (Tegobuvir), a Novel Nonnucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase

2011 • 91 citations

Directly acting antivirals for the treatment of patients with hepatitis C infection: A clinical development update addressing key future challenges

2008 • 72 citations

Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients

1998 • 65 citations

1356 QUADRUPLE THERAPY WITH BMS-790052, BMS-650032 AND PEG-IFN/RBV FOR 24 WEEKS RESULTS IN 100% SVR12 IN HCV GENOTYPE 1 NULL RESPONDERS

2011 • 64 citations

Review: New direct-acting antivirals in the development for hepatitis C virus infection

2010 • 59 citations

1370 ONCE DAILY DUAL-NUCLEOTIDE COMBINATION OF PSI-938 AND PSI-7977 PROVIDES 94% HCVRNA <LOD AT DAY 14: FIRST PURINE/PYRIMIDINE CLINICAL COMBINATION DATA (THE NUCLEAR STUDY)

2011 • 49 citations

39 Valopicitabine (NM283), alone or with peginterferon, compared to peg interferon/ribavirin (pegifn/RBV) re-treatment in hepatitis patients with prior non-response to PEGIFN/RBV: Week 24 results

2006 • 35 citations

1363 VX-222 WITH TVR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C: ZENITH STUDY INTERIM RESULTS

2011 • 27 citations

445 A PHASE 2B TRIAL COMPARING 24 TO 48 WEEKS TREATMENT WITH TEGOBUVIR (GS-9190)/PEG/RBV TO 48 WEEKS TREATMENT WITH PEG/RBV FOR CHRONIC GENOTYPE 1 HCV INFECTION

2011 • 24 citations

1236 MECHANISMS OF ISOLATED UNCONJUGATED HYPERBILIRUBINEMIA INDUCED BY THE HCV NS3/4A PROTEASE INHIBITOR BI201335

2011 • 18 citations

2008 DOSE-RANGING, THREE-DAY MONOTHERAPY STUDY OF THE HCV NS3 PROTEASE INHIBITOR GS-9256

2010 • 11 citations